SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on March 25, 2021. The report serves to disclose the Company's financial results for the quarter and full year ended December 31, 2020, via a press release furnished as Exhibit 99.1. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of results for the period ended December 31, 2020.
Guidance, Outlook, and Risks
Under Item 7.01, the Company outlines its Regulation FD disclosure policy, stating that material information is disseminated through SEC filings, press releases, conference calls, and social media channels (Twitter, LinkedIn, Facebook). The filing explicitly states that the information furnished under Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached press release (Exhibit 99.1) referenced in this filing.
- Confirm the Company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Review the Company's official investor relations website and social media channels for any additional material disclosures made concurrently with this filing.
- Note that the filing text itself does not contain the detailed financial data required for quantitative analysis.